Global Sleep Disorders Market

Sleep Disorders Comprehensive Study by Type (Mattresses and Pillows, Sleep Laboratories, Medications, Sleep Disorder Devices), Category (Insomnia, Hypersomnia, Sleep apnea, Sleep breathing disorders, Circadian rhythm disorders, Parasomnia, Sleep movement disorders, Others), Treatment (Psychiatric treatment, Behavioral treatment, Cognitive behavioral therapy, Medication therapy, Others), Medication (Prescription-based Drugs, OTC Drugs, Herbal Drugs) Players and Region - Global Market Outlook to 2026

Sleep Disorders Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Sleep Disorders Market Overview:
Sleep disorders are a bunch of conditions that have an effect on the ability to sleep well on a daily basis. Whether or not they are caused by a health problem or by an excessive amount of stress, sleep disorders are getting progressively common across the world. Most people sometimes experience sleeping problems because of stress, hectic schedules, and different outside influences. However, once these issues begin to occur on an everyday basis and interfere with daily life, they may indicate a sleeping disorder. Depending on the kind of disorder, people could have a difficult time falling asleep and may feel extremely tired throughout the day. The shortage of sleep can have a negative impact on energy, mood, concentration, and overall health. Some of the players profiled in the study are GlaxoSmithKline plc (United Kingdom), Becton Dickson and Company (United States), Natus Medical Incorporated (United States), Cardinal Health (United States), Koninklijke Philips N.V. (Netherlands), Teva Pharmaceutical Industries Ltd. (Israel), Takeda Pharmaceutical Company Limited (Japan), fizer Inc (United States), Sanofi (France) and Merck & Co Inc (United States).

On the basis of geography, the market of Sleep Disorders has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Category, the sub-segment i.e. Insomnia will boost the Sleep Disorders market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Psychiatric treatment will boost the Sleep Disorders market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Medication, the sub-segment i.e. Prescription-based Drugs will boost the Sleep Disorders market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Significant Rise in the Prevalence of Sleep Disorders
  • The Increasing Usage of Social Media and Growing Addiction of Gadgets
  • Ongoing Research on Ill-Effects of Sleep Deprivation
  • The Growing Adoption of Sleep Clinics


Restraints
  • Increase in Patent Expirations
  • Emergence of Generics
  • Side-Effects Associated With Sleep Disorder Drugs

Opportunities
  • The Rising Demand from Developed & Developing Countries
  • Introduction of Home Sleep Test Kits
  • Utilization of Wearable Monitors & Continuous Positive Airway Pressure (CPAP) Therapy


Key Market Developments:


On Feb. 27, 2018 The Center for Craniofacial & Dental Sleep Medicine (CFDSM), a Houston-based company specializing in dental sleep medicine and sleep apnea treatment, announced that it has received FDA clearance on its innovative new treatment for obstructive sleep apnea (OSA) and snoring, The Meridian PM oral appliance.

Target Audience:
Sleeping Disorder treatment product manufacturers, Sleeping Disorder treatment dealers and suppliers, Sleeping Disorder associations, Academic institutions, Venture capitalists, Consulting firms and Government bodies

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Sleep Disorders market on the basis of product [Mattresses and Pillows, Sleep Laboratories, Medications and Sleep Disorder Devices] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Sleep Disorders market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Sleep Disorders industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are GlaxoSmithKline plc (United Kingdom) and Natus Medical Incorporated (United States).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Sleep Disorders market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Mattresses and Pillows
  • Sleep Laboratories
  • Medications
  • Sleep Disorder Devices
By Category
  • Insomnia
  • Hypersomnia
  • Sleep apnea
  • Sleep breathing disorders
  • Circadian rhythm disorders
  • Parasomnia
  • Sleep movement disorders
  • Others

By Treatment
  • Psychiatric treatment
  • Behavioral treatment
  • Cognitive behavioral therapy
  • Medication therapy
  • Others

By Medication
  • Prescription-based Drugs
  • OTC Drugs
  • Herbal Drugs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Significant Rise in the Prevalence of Sleep Disorders
      • 3.2.2. The Increasing Usage of Social Media and Growing Addiction of Gadgets
      • 3.2.3. Ongoing Research on Ill-Effects of Sleep Deprivation
      • 3.2.4. The Growing Adoption of Sleep Clinics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sleep Disorders, by Type, Category, Treatment, Medication and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Sleep Disorders (Value)
      • 5.2.1. Global Sleep Disorders by: Type (Value)
        • 5.2.1.1. Mattresses and Pillows
        • 5.2.1.2. Sleep Laboratories
        • 5.2.1.3. Medications
        • 5.2.1.4. Sleep Disorder Devices
      • 5.2.2. Global Sleep Disorders by: Category (Value)
        • 5.2.2.1. Insomnia
        • 5.2.2.2. Hypersomnia
        • 5.2.2.3. Sleep apnea
        • 5.2.2.4. Sleep breathing disorders
        • 5.2.2.5. Circadian rhythm disorders
        • 5.2.2.6. Parasomnia
        • 5.2.2.7. Sleep movement disorders
        • 5.2.2.8. Others
      • 5.2.3. Global Sleep Disorders by: Treatment (Value)
        • 5.2.3.1. Psychiatric treatment
        • 5.2.3.2. Behavioral treatment
        • 5.2.3.3. Cognitive behavioral therapy
        • 5.2.3.4. Medication therapy
        • 5.2.3.5. Others
      • 5.2.4. Global Sleep Disorders by: Medication (Value)
        • 5.2.4.1. Prescription-based Drugs
        • 5.2.4.2. OTC Drugs
        • 5.2.4.3. Herbal Drugs
      • 5.2.5. Global Sleep Disorders Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Sleep Disorders: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Becton Dickson and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Natus Medical Incorporated (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cardinal Health (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Koninklijke Philips N.V. (Netherlands)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Fizer Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Co Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Sleep Disorders Sale, by Type, Category, Treatment, Medication and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Sleep Disorders (Value)
      • 7.2.1. Global Sleep Disorders by: Type (Value)
        • 7.2.1.1. Mattresses and Pillows
        • 7.2.1.2. Sleep Laboratories
        • 7.2.1.3. Medications
        • 7.2.1.4. Sleep Disorder Devices
      • 7.2.2. Global Sleep Disorders by: Category (Value)
        • 7.2.2.1. Insomnia
        • 7.2.2.2. Hypersomnia
        • 7.2.2.3. Sleep apnea
        • 7.2.2.4. Sleep breathing disorders
        • 7.2.2.5. Circadian rhythm disorders
        • 7.2.2.6. Parasomnia
        • 7.2.2.7. Sleep movement disorders
        • 7.2.2.8. Others
      • 7.2.3. Global Sleep Disorders by: Treatment (Value)
        • 7.2.3.1. Psychiatric treatment
        • 7.2.3.2. Behavioral treatment
        • 7.2.3.3. Cognitive behavioral therapy
        • 7.2.3.4. Medication therapy
        • 7.2.3.5. Others
      • 7.2.4. Global Sleep Disorders by: Medication (Value)
        • 7.2.4.1. Prescription-based Drugs
        • 7.2.4.2. OTC Drugs
        • 7.2.4.3. Herbal Drugs
      • 7.2.5. Global Sleep Disorders Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sleep Disorders: by Type(USD Million)
  • Table 2. Sleep Disorders Mattresses and Pillows , by Region USD Million (2015-2020)
  • Table 3. Sleep Disorders Sleep Laboratories , by Region USD Million (2015-2020)
  • Table 4. Sleep Disorders Medications , by Region USD Million (2015-2020)
  • Table 5. Sleep Disorders Sleep Disorder Devices , by Region USD Million (2015-2020)
  • Table 6. Sleep Disorders: by Category(USD Million)
  • Table 7. Sleep Disorders Insomnia , by Region USD Million (2015-2020)
  • Table 8. Sleep Disorders Hypersomnia , by Region USD Million (2015-2020)
  • Table 9. Sleep Disorders Sleep apnea , by Region USD Million (2015-2020)
  • Table 10. Sleep Disorders Sleep breathing disorders , by Region USD Million (2015-2020)
  • Table 11. Sleep Disorders Circadian rhythm disorders , by Region USD Million (2015-2020)
  • Table 12. Sleep Disorders Parasomnia , by Region USD Million (2015-2020)
  • Table 13. Sleep Disorders Sleep movement disorders , by Region USD Million (2015-2020)
  • Table 14. Sleep Disorders Others , by Region USD Million (2015-2020)
  • Table 15. Sleep Disorders: by Treatment(USD Million)
  • Table 16. Sleep Disorders Psychiatric treatment , by Region USD Million (2015-2020)
  • Table 17. Sleep Disorders Behavioral treatment , by Region USD Million (2015-2020)
  • Table 18. Sleep Disorders Cognitive behavioral therapy , by Region USD Million (2015-2020)
  • Table 19. Sleep Disorders Medication therapy , by Region USD Million (2015-2020)
  • Table 20. Sleep Disorders Others , by Region USD Million (2015-2020)
  • Table 21. Sleep Disorders: by Medication(USD Million)
  • Table 22. Sleep Disorders Prescription-based Drugs , by Region USD Million (2015-2020)
  • Table 23. Sleep Disorders OTC Drugs , by Region USD Million (2015-2020)
  • Table 24. Sleep Disorders Herbal Drugs , by Region USD Million (2015-2020)
  • Table 25. South America Sleep Disorders, by Country USD Million (2015-2020)
  • Table 26. South America Sleep Disorders, by Type USD Million (2015-2020)
  • Table 27. South America Sleep Disorders, by Category USD Million (2015-2020)
  • Table 28. South America Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 29. South America Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 30. Brazil Sleep Disorders, by Type USD Million (2015-2020)
  • Table 31. Brazil Sleep Disorders, by Category USD Million (2015-2020)
  • Table 32. Brazil Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 33. Brazil Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 34. Argentina Sleep Disorders, by Type USD Million (2015-2020)
  • Table 35. Argentina Sleep Disorders, by Category USD Million (2015-2020)
  • Table 36. Argentina Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 37. Argentina Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 38. Rest of South America Sleep Disorders, by Type USD Million (2015-2020)
  • Table 39. Rest of South America Sleep Disorders, by Category USD Million (2015-2020)
  • Table 40. Rest of South America Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 41. Rest of South America Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 42. Asia Pacific Sleep Disorders, by Country USD Million (2015-2020)
  • Table 43. Asia Pacific Sleep Disorders, by Type USD Million (2015-2020)
  • Table 44. Asia Pacific Sleep Disorders, by Category USD Million (2015-2020)
  • Table 45. Asia Pacific Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 46. Asia Pacific Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 47. China Sleep Disorders, by Type USD Million (2015-2020)
  • Table 48. China Sleep Disorders, by Category USD Million (2015-2020)
  • Table 49. China Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 50. China Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 51. Japan Sleep Disorders, by Type USD Million (2015-2020)
  • Table 52. Japan Sleep Disorders, by Category USD Million (2015-2020)
  • Table 53. Japan Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 54. Japan Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 55. India Sleep Disorders, by Type USD Million (2015-2020)
  • Table 56. India Sleep Disorders, by Category USD Million (2015-2020)
  • Table 57. India Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 58. India Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 59. South Korea Sleep Disorders, by Type USD Million (2015-2020)
  • Table 60. South Korea Sleep Disorders, by Category USD Million (2015-2020)
  • Table 61. South Korea Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 62. South Korea Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 63. Taiwan Sleep Disorders, by Type USD Million (2015-2020)
  • Table 64. Taiwan Sleep Disorders, by Category USD Million (2015-2020)
  • Table 65. Taiwan Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 66. Taiwan Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 67. Australia Sleep Disorders, by Type USD Million (2015-2020)
  • Table 68. Australia Sleep Disorders, by Category USD Million (2015-2020)
  • Table 69. Australia Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 70. Australia Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Sleep Disorders, by Type USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Sleep Disorders, by Category USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 75. Europe Sleep Disorders, by Country USD Million (2015-2020)
  • Table 76. Europe Sleep Disorders, by Type USD Million (2015-2020)
  • Table 77. Europe Sleep Disorders, by Category USD Million (2015-2020)
  • Table 78. Europe Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 79. Europe Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 80. Germany Sleep Disorders, by Type USD Million (2015-2020)
  • Table 81. Germany Sleep Disorders, by Category USD Million (2015-2020)
  • Table 82. Germany Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 83. Germany Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 84. France Sleep Disorders, by Type USD Million (2015-2020)
  • Table 85. France Sleep Disorders, by Category USD Million (2015-2020)
  • Table 86. France Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 87. France Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 88. Italy Sleep Disorders, by Type USD Million (2015-2020)
  • Table 89. Italy Sleep Disorders, by Category USD Million (2015-2020)
  • Table 90. Italy Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 91. Italy Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 92. United Kingdom Sleep Disorders, by Type USD Million (2015-2020)
  • Table 93. United Kingdom Sleep Disorders, by Category USD Million (2015-2020)
  • Table 94. United Kingdom Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 95. United Kingdom Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 96. Netherlands Sleep Disorders, by Type USD Million (2015-2020)
  • Table 97. Netherlands Sleep Disorders, by Category USD Million (2015-2020)
  • Table 98. Netherlands Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 99. Netherlands Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 100. Rest of Europe Sleep Disorders, by Type USD Million (2015-2020)
  • Table 101. Rest of Europe Sleep Disorders, by Category USD Million (2015-2020)
  • Table 102. Rest of Europe Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 103. Rest of Europe Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 104. MEA Sleep Disorders, by Country USD Million (2015-2020)
  • Table 105. MEA Sleep Disorders, by Type USD Million (2015-2020)
  • Table 106. MEA Sleep Disorders, by Category USD Million (2015-2020)
  • Table 107. MEA Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 108. MEA Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 109. Middle East Sleep Disorders, by Type USD Million (2015-2020)
  • Table 110. Middle East Sleep Disorders, by Category USD Million (2015-2020)
  • Table 111. Middle East Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 112. Middle East Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 113. Africa Sleep Disorders, by Type USD Million (2015-2020)
  • Table 114. Africa Sleep Disorders, by Category USD Million (2015-2020)
  • Table 115. Africa Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 116. Africa Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 117. North America Sleep Disorders, by Country USD Million (2015-2020)
  • Table 118. North America Sleep Disorders, by Type USD Million (2015-2020)
  • Table 119. North America Sleep Disorders, by Category USD Million (2015-2020)
  • Table 120. North America Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 121. North America Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 122. United States Sleep Disorders, by Type USD Million (2015-2020)
  • Table 123. United States Sleep Disorders, by Category USD Million (2015-2020)
  • Table 124. United States Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 125. United States Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 126. Canada Sleep Disorders, by Type USD Million (2015-2020)
  • Table 127. Canada Sleep Disorders, by Category USD Million (2015-2020)
  • Table 128. Canada Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 129. Canada Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 130. Mexico Sleep Disorders, by Type USD Million (2015-2020)
  • Table 131. Mexico Sleep Disorders, by Category USD Million (2015-2020)
  • Table 132. Mexico Sleep Disorders, by Treatment USD Million (2015-2020)
  • Table 133. Mexico Sleep Disorders, by Medication USD Million (2015-2020)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Sleep Disorders: by Type(USD Million)
  • Table 145. Sleep Disorders Mattresses and Pillows , by Region USD Million (2021-2026)
  • Table 146. Sleep Disorders Sleep Laboratories , by Region USD Million (2021-2026)
  • Table 147. Sleep Disorders Medications , by Region USD Million (2021-2026)
  • Table 148. Sleep Disorders Sleep Disorder Devices , by Region USD Million (2021-2026)
  • Table 149. Sleep Disorders: by Category(USD Million)
  • Table 150. Sleep Disorders Insomnia , by Region USD Million (2021-2026)
  • Table 151. Sleep Disorders Hypersomnia , by Region USD Million (2021-2026)
  • Table 152. Sleep Disorders Sleep apnea , by Region USD Million (2021-2026)
  • Table 153. Sleep Disorders Sleep breathing disorders , by Region USD Million (2021-2026)
  • Table 154. Sleep Disorders Circadian rhythm disorders , by Region USD Million (2021-2026)
  • Table 155. Sleep Disorders Parasomnia , by Region USD Million (2021-2026)
  • Table 156. Sleep Disorders Sleep movement disorders , by Region USD Million (2021-2026)
  • Table 157. Sleep Disorders Others , by Region USD Million (2021-2026)
  • Table 158. Sleep Disorders: by Treatment(USD Million)
  • Table 159. Sleep Disorders Psychiatric treatment , by Region USD Million (2021-2026)
  • Table 160. Sleep Disorders Behavioral treatment , by Region USD Million (2021-2026)
  • Table 161. Sleep Disorders Cognitive behavioral therapy , by Region USD Million (2021-2026)
  • Table 162. Sleep Disorders Medication therapy , by Region USD Million (2021-2026)
  • Table 163. Sleep Disorders Others , by Region USD Million (2021-2026)
  • Table 164. Sleep Disorders: by Medication(USD Million)
  • Table 165. Sleep Disorders Prescription-based Drugs , by Region USD Million (2021-2026)
  • Table 166. Sleep Disorders OTC Drugs , by Region USD Million (2021-2026)
  • Table 167. Sleep Disorders Herbal Drugs , by Region USD Million (2021-2026)
  • Table 168. South America Sleep Disorders, by Country USD Million (2021-2026)
  • Table 169. South America Sleep Disorders, by Type USD Million (2021-2026)
  • Table 170. South America Sleep Disorders, by Category USD Million (2021-2026)
  • Table 171. South America Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 172. South America Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 173. Brazil Sleep Disorders, by Type USD Million (2021-2026)
  • Table 174. Brazil Sleep Disorders, by Category USD Million (2021-2026)
  • Table 175. Brazil Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 176. Brazil Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 177. Argentina Sleep Disorders, by Type USD Million (2021-2026)
  • Table 178. Argentina Sleep Disorders, by Category USD Million (2021-2026)
  • Table 179. Argentina Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 180. Argentina Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 181. Rest of South America Sleep Disorders, by Type USD Million (2021-2026)
  • Table 182. Rest of South America Sleep Disorders, by Category USD Million (2021-2026)
  • Table 183. Rest of South America Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 184. Rest of South America Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 185. Asia Pacific Sleep Disorders, by Country USD Million (2021-2026)
  • Table 186. Asia Pacific Sleep Disorders, by Type USD Million (2021-2026)
  • Table 187. Asia Pacific Sleep Disorders, by Category USD Million (2021-2026)
  • Table 188. Asia Pacific Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 189. Asia Pacific Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 190. China Sleep Disorders, by Type USD Million (2021-2026)
  • Table 191. China Sleep Disorders, by Category USD Million (2021-2026)
  • Table 192. China Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 193. China Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 194. Japan Sleep Disorders, by Type USD Million (2021-2026)
  • Table 195. Japan Sleep Disorders, by Category USD Million (2021-2026)
  • Table 196. Japan Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 197. Japan Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 198. India Sleep Disorders, by Type USD Million (2021-2026)
  • Table 199. India Sleep Disorders, by Category USD Million (2021-2026)
  • Table 200. India Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 201. India Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 202. South Korea Sleep Disorders, by Type USD Million (2021-2026)
  • Table 203. South Korea Sleep Disorders, by Category USD Million (2021-2026)
  • Table 204. South Korea Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 205. South Korea Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 206. Taiwan Sleep Disorders, by Type USD Million (2021-2026)
  • Table 207. Taiwan Sleep Disorders, by Category USD Million (2021-2026)
  • Table 208. Taiwan Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 209. Taiwan Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 210. Australia Sleep Disorders, by Type USD Million (2021-2026)
  • Table 211. Australia Sleep Disorders, by Category USD Million (2021-2026)
  • Table 212. Australia Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 213. Australia Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Sleep Disorders, by Type USD Million (2021-2026)
  • Table 215. Rest of Asia-Pacific Sleep Disorders, by Category USD Million (2021-2026)
  • Table 216. Rest of Asia-Pacific Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 217. Rest of Asia-Pacific Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 218. Europe Sleep Disorders, by Country USD Million (2021-2026)
  • Table 219. Europe Sleep Disorders, by Type USD Million (2021-2026)
  • Table 220. Europe Sleep Disorders, by Category USD Million (2021-2026)
  • Table 221. Europe Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 222. Europe Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 223. Germany Sleep Disorders, by Type USD Million (2021-2026)
  • Table 224. Germany Sleep Disorders, by Category USD Million (2021-2026)
  • Table 225. Germany Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 226. Germany Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 227. France Sleep Disorders, by Type USD Million (2021-2026)
  • Table 228. France Sleep Disorders, by Category USD Million (2021-2026)
  • Table 229. France Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 230. France Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 231. Italy Sleep Disorders, by Type USD Million (2021-2026)
  • Table 232. Italy Sleep Disorders, by Category USD Million (2021-2026)
  • Table 233. Italy Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 234. Italy Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 235. United Kingdom Sleep Disorders, by Type USD Million (2021-2026)
  • Table 236. United Kingdom Sleep Disorders, by Category USD Million (2021-2026)
  • Table 237. United Kingdom Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 238. United Kingdom Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 239. Netherlands Sleep Disorders, by Type USD Million (2021-2026)
  • Table 240. Netherlands Sleep Disorders, by Category USD Million (2021-2026)
  • Table 241. Netherlands Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 242. Netherlands Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 243. Rest of Europe Sleep Disorders, by Type USD Million (2021-2026)
  • Table 244. Rest of Europe Sleep Disorders, by Category USD Million (2021-2026)
  • Table 245. Rest of Europe Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 246. Rest of Europe Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 247. MEA Sleep Disorders, by Country USD Million (2021-2026)
  • Table 248. MEA Sleep Disorders, by Type USD Million (2021-2026)
  • Table 249. MEA Sleep Disorders, by Category USD Million (2021-2026)
  • Table 250. MEA Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 251. MEA Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 252. Middle East Sleep Disorders, by Type USD Million (2021-2026)
  • Table 253. Middle East Sleep Disorders, by Category USD Million (2021-2026)
  • Table 254. Middle East Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 255. Middle East Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 256. Africa Sleep Disorders, by Type USD Million (2021-2026)
  • Table 257. Africa Sleep Disorders, by Category USD Million (2021-2026)
  • Table 258. Africa Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 259. Africa Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 260. North America Sleep Disorders, by Country USD Million (2021-2026)
  • Table 261. North America Sleep Disorders, by Type USD Million (2021-2026)
  • Table 262. North America Sleep Disorders, by Category USD Million (2021-2026)
  • Table 263. North America Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 264. North America Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 265. United States Sleep Disorders, by Type USD Million (2021-2026)
  • Table 266. United States Sleep Disorders, by Category USD Million (2021-2026)
  • Table 267. United States Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 268. United States Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 269. Canada Sleep Disorders, by Type USD Million (2021-2026)
  • Table 270. Canada Sleep Disorders, by Category USD Million (2021-2026)
  • Table 271. Canada Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 272. Canada Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 273. Mexico Sleep Disorders, by Type USD Million (2021-2026)
  • Table 274. Mexico Sleep Disorders, by Category USD Million (2021-2026)
  • Table 275. Mexico Sleep Disorders, by Treatment USD Million (2021-2026)
  • Table 276. Mexico Sleep Disorders, by Medication USD Million (2021-2026)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sleep Disorders: by Type USD Million (2015-2020)
  • Figure 5. Global Sleep Disorders: by Category USD Million (2015-2020)
  • Figure 6. Global Sleep Disorders: by Treatment USD Million (2015-2020)
  • Figure 7. Global Sleep Disorders: by Medication USD Million (2015-2020)
  • Figure 8. South America Sleep Disorders Share (%), by Country
  • Figure 9. Asia Pacific Sleep Disorders Share (%), by Country
  • Figure 10. Europe Sleep Disorders Share (%), by Country
  • Figure 11. MEA Sleep Disorders Share (%), by Country
  • Figure 12. North America Sleep Disorders Share (%), by Country
  • Figure 13. Global Sleep Disorders share by Players 2020 (%)
  • Figure 14. Global Sleep Disorders share by Players (Top 3) 2020(%)
  • Figure 15. Global Sleep Disorders share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Becton Dickson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Becton Dickson and Company (United States) Revenue: by Geography 2020
  • Figure 21. Natus Medical Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 22. Natus Medical Incorporated (United States) Revenue: by Geography 2020
  • Figure 23. Cardinal Health (United States) Revenue, Net Income and Gross profit
  • Figure 24. Cardinal Health (United States) Revenue: by Geography 2020
  • Figure 25. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 26. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 27. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 29. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2020
  • Figure 31. Fizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. Fizer Inc (United States) Revenue: by Geography 2020
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2020
  • Figure 35. Merck & Co Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co Inc (United States) Revenue: by Geography 2020
  • Figure 37. Global Sleep Disorders: by Type USD Million (2021-2026)
  • Figure 38. Global Sleep Disorders: by Category USD Million (2021-2026)
  • Figure 39. Global Sleep Disorders: by Treatment USD Million (2021-2026)
  • Figure 40. Global Sleep Disorders: by Medication USD Million (2021-2026)
  • Figure 41. South America Sleep Disorders Share (%), by Country
  • Figure 42. Asia Pacific Sleep Disorders Share (%), by Country
  • Figure 43. Europe Sleep Disorders Share (%), by Country
  • Figure 44. MEA Sleep Disorders Share (%), by Country
  • Figure 45. North America Sleep Disorders Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Becton Dickson and Company (United States)
  • Natus Medical Incorporated (United States)
  • Cardinal Health (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Takeda Pharmaceutical Company Limited (Japan)
  • fizer Inc (United States)
  • Sanofi (France)
  • Merck & Co Inc (United States)
Additional players considered in the study are as follows:
GlaxoSmithKline plc (United Kingdom) , Natus Medical Incorporated (United States)
Select User Access Type

Key Highlights of Report


Jun 2021 150 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Sleep Disorders Market Quantitative research analysis
Global Sleep Disorders Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Sleep Disorders Market Report?

Have a Query? Click Here

Other Related Reports

Throat Lozenges Comprehensive Study by Type (Hard Candy Lozenges, Soft Lozenges, Compressed Lozenges), Application (Pharmacy, Convenience Store, Other), Composition (Pectin Composition, Zinc Gluconat...
$ 3650
Bone Putty Comprehensive Study by Application (Orthopedic Surgery, Dental Surgery), End-users (Hospitals, Ambulatory Surgical Centers, Clinics, Others) Players and Region - Global Market Outlook to 2...
$ 3500
Critical Care diagnostics Comprehensive Study by Test (Flow Cytometry, Hematology Test, Microbiology and Infectious Test, Coagulation Test, Immunoprotein, Routine and Special Chemistry, Others), End ...
$ 3450
Familial Adenomatous Polyposis Treatment Comprehensive Study by Type (Icosapent, Eflornithine Hydrochloride, Aspirin, CEQ-508, Others), Application (Clinic, Hospital, Others), Familial Adenomatous Po...
$ 3750
Aromatherapy Essential Oil Comprehensive Study by Type (Lavender, Peppermint, Lemon, Tea Tree, Bergamot, Rosemary, Eucalyptus, Ginger, Geranium, Mandarin), Application (Cosmetic, Massage, Medical, Ol...
$ 3450
Asthma Therapeutics Comprehensive Study by Type (Dry Powder Inhalers, Metered Dose Inhalers, Mist Inhalers, Nebulizer), Route Of Administration (Inhalation, Oral, Parenteral), Drug Class (Anti-Inflam...
$ 3650